Methods for treating pain by administering a nerve growth factor antagonist and an opioid analgesic and compositions containing the same

• US 20040131615A1
• Filed: 10/08/2003
• Published: 07/08/2004
• Est. Priority Date: 10/08/2002
• Status: Abandoned Application

• Current Assignee: Rinat Neuroscience Corp. (Pfizer Inc.)
• Original Assignee: Rinat Neuroscience Corp. (Pfizer Inc.)
• Inventors: Vergara, German J., Shelton, David L.
• Application Number:
  US10/682,332
• Publication Number:
  US 20040131615A1
• Time in Patent Office: Days
• US Class Current: 424/145.1
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/485 Morphinan derivatives, e.g. morphine, codeine
• CPC Class Codes: A61K 39/3955 against proteinaceous materials, e.g. enzymes, hormones, lymphokines
• CPC Class Codes: A61P 25/04 Centrally acting analgesics, e.g. opioids
• CPC Class Codes: C07K 16/22 against growth factors ; against growth regulators
• CPC Class Codes: C07K 2317/76 Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

The present invention features methods for treating or preventing pain comprising administering an amount of a nerve growth factor antagonist and an amount of an opioid analgesic such that together they provide effective pain relief. The invention also features compositions comprising a nerve growth factor antagonist and an opioid analgesic and kits containing the same.

Claims

1. A method for treating pain in an individual comprising administering to the individual an amount of an anti-nerve growth factor (NGF) antibody and an amount of an opioid analgesic, whereby the anti-NGF antibody and the opioid analgesic in conjunction provide effective pain relief.

2. The method of claim 1, wherein the opioid analgesic is selected from the group consisting of morphine, codeine, dihydrocodeine, diacetylmorphine, hydrocodone, hydromorphone, levorphanol, oxymorphone, alfentanil, buprenorphine, butorphanol, fentanyl, sufentanyl, meperidine, methadone, nalbuphine, propoxyphene and pentazocine.

3. The method of claim 2, wherein the opioid analgesic is morphine.

4. The method of claim 1 or 3, wherein the anti-NGF antibody binds human NGF.

5. The method of claim 4, wherein the anti-NGF antibody binds human NGF with a binding affinity of about 10 nM or less than about 10 nM.

6. The method of claim 1, wherein the anti-NGF antibody is a human antibody.

7. The method of claim 1, wherein the anti-NGF antibody is a humanized antibody.

8. The method of claim 1, wherein the pain is post-surgical pain.

9. The method of claim 4, wherein the pain is post-surgical pain.

10. A pharmaceutical composition for treating pain comprising an effective amount of an anti-NGF antibody and an opioid analgesic, and a pharmaceutically acceptable carrier.

11. A kit for treating pain comprising an anti-NGF antibody, an opioid analgesic, and instructions for administering the anti-NGF antibody in conjunction with the opioid analgesic to treat pain.